Myristoyl Tetrapeptide-12 | CAS:959610-24-3

We serve Myristoyl Tetrapeptide-12 CAS:959610-24-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Myristoyl Tetrapeptide-12

Chemical Name:Myristoyl Tetrapeptide-12
CAS.NO:959610-24-3
Synonyms:Myristoyl Tetrapeptide-12
N2-Tetradecanoyl-L-lysyl-L-alanyl-L-lysyl-L-alaninamide
N2-(1-Oxotetradecyl)-L-lysyl-L-alanyl-L-lysyl-L-alaninamide
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 932.2±65.0 °C at 760 mmHg
Molecular Formula C32H63N7O5
Molecular Weight 625.886
Flash Point 517.6±34.3 °C
Vapour Pressure 0.0±0.3 mmHg at 25°C
Index of Refraction 1.506
 
Specification:
Appearance:White to off-white powder
Assay:≥95.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Promote eyelash growth.



Contact us for information like Myristoyl Tetrapeptide-12 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N2-(1-Oxotetradecyl)-L-lysyl-L-alanyl-L-lysyl-L-alaninamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Myristoyl Tetrapeptide-12 Use and application,Myristoyl Tetrapeptide-12 technical grade,usp/ep/jp grade.


Related News: In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers.Fmoc-beta-cyclohexyl-D-alanine manufacturer In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers.(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol supplier Domestic API companies cooperate with major international companies through commissioned processing, patent transfer, and joint venture production.3-Piperazinobenzisothiazole Hydrochloride vendor Here’s what we can tell you so far:We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.